At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Moderate to severe rosacea (IGA score 3 or 4)
- ✓15–50 facial papules and pustules, excluding lesions on eyes and scalp
- ✓No more than 2 nodules on the face
- ✕Pregnant, lactating, or planning pregnancy during study
- ✕Hypersensitivity or allergy to tetracyclines or formulation components
- ✕History of C. difficile–associated colitis or intracranial hypertension
- ✕Moderate or severe rhinophyma, dense telangiectasia, or plaque-like facial edema
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study on the Use of Seysara for Rosacea
In Brief
A Phase 4 clinical trial evaluating sarecycline and Centrum Adult Multivitamin for Acne Rosacea. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)
Study Details
Timeline
Interventions
sarecycline tablet
Centrum Adult Mulltivitamin tablet